View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 16, 2015

AbbVie presents SURVEYOR study results for its investigational HCV regimen

Biopharmaceutical company AbbVie has presented data from the SURVEYOR studies of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor.

<a href=AbbVie ” height=”215″ src=”https://www.drugdevelopment-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/Abbb.JPG” style=”padding: 10px” width=”307″ />

Biopharmaceutical company AbbVie has presented data from the Surveyor studies of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

ABT-493 is the result of an ongoing partnership between AbbVie and Enanta Pharmaceuticals for HCV protease inhibitors and regimens, including protease inhibitors.

The inhibitor is being developed for use in combination with AbbVie ‘s other investigational medicines for the treatment of hepatitis C.

At 12 weeks post-treatment (SVR12), the data showed high rates of sustained virologic response in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection.

SVR12 rates were 97-100% in genotype 1 (GT1), 96-100% in genotype 2 (GT2) and 83-94% in genotype 3 (GT3) patients after 12 weeks of treatment.

In the Surveyor -I study non-cirrhotic GT1 chronic HCV patients, who received a shorter eight-week treatment, achieved an SVR12 rate of 97%.

AbbVie chief scientific officer Dr Michael Severino said: "The Surveyor trials offer important new information about the potential to treat patients with chronic hepatitis C across multiple genotypes with our two direct-acting antiviral investigational regimen.

"AbbVie ‘s ongoing hepatitis C research program demonstrates our commitment to make a remarkable impact on the lives of HCV patients."

Surveyor -I and Surveyor -II are ongoing Phase II clinical studies to assess the safety and efficacy of ABT-493 and ABT-530, with or without ribavirin (RBV), for eight to 12 weeks.

According to AbbVie , data in non-cirrhotic patients with GT4, GT5, and GT6 chronic HCV infection will be presented in the near future.

A multinational Phase III programme, initiated earlier in November, will evaluate ABT-493 and ABT-530 in genotypes 1 through 6.


Image: Electron micrographs of hepatitis C virus purified from cell culture. Photo: courtesy of Charles Rice / Center for the Study of Hepatitis C, The Rockefeller University.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena